Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Oxoferin for lupoid leishmaniasis
IRCT20190114042356N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tetrachlorodecaoxide in Leishmaniasis recidivans (LR), sponsored by Mashhad University of Medical Sciences. Primary endpoint: Therapeutic response of lesion. Started Feb 2019; status: completed.
02
Drugs
tetrachlorodecaoxide
03
Conditions
Leishmaniasis recidivans (LR)
Beyond the preview
Go deeper on IRCT20190114042356N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190114042356N1.